Safety and effectiveness of Imjudo and Imfinzi in real-world liver cancer patients
Studies safety and effectiveness of Imjudo and Imfinzi in people with liver cancer.
Plain-language title generated from the registry record
Registry title: Imjudo & Imfinzi PMS
Key facts
- Where
- Busan, Goyang, Seongnam, Seoul, and Suwon, South KoreaSee the 5 sites
Where in South Korea
- BusanBusan, South KoreaTaking people
- GoyangGoyang, South KoreaTaking people
- SeongnamSeongnam, South KoreaTaking people
- SeoulSeoul, South KoreaTaking people
- SuwonSuwon, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06544629
- Record updated
- 5 October 2026
- Original description
Based on the re-review of new drugs article, Korean pharmaceutical act, the objectives of this study are to assess safety and effectiveness of the study drugs(Imjudo \& Imfinzi) in a real world setting in patients who treated according to the approved indications in Korea.Read full original descriptionShow less
Imjudo & Imfinzi Post-Marketing Surveillance
Based on the re-review of new drugs article, Korean pharmaceutical act, the objectives of this study are to assess safety and effectiveness of the study drugs(Imjudo \& Imfinzi) in a real world setting in patients who treated according to the approved indications in Korea.
Inclusion: Patients eligible for the study drugs according to the approved label in Korea; Provision of signed and dated written informed consent by the patient or legally acceptable representative.
Exclusion: Other off-label indications according to the approved label in South Korea; Current participation in any interventional trial.